Blocking NF-κB and Akt by Hsp90 inhibition sensitizes Smac mimetic compound 3-induced extrinsic apoptosis pathway and results in synergistic cancer cell death
Authors:
- 23 September 2010
- journal article
- research article
- Published by Springer Nature in Apoptosis
- Vol. 16 (1) , 45-54
Abstract
NF-κB and Akt are two main cell survival pathways that attenuate the anticancer efficacy of therapeutics. Our previous studies demonstrated that the Smac mimetic compound 3 (SMC3) specifically suppresses c-IAP1 and induces TNF-α autocrine to kill cancer cells. However, SMC3 also induces a cell survival signal through NF-κB activation. In this report, we further found that SMC3 potently activates Akt, which inhibits SMC3-induced cancer cell death. Strikingly, concurrent blocking NF-κB and Akt resulted in a significantly potentiated cytotoxicity. Because heat shock protein 90 (Hsp90) plays an important role in maintaining the integrity of both the NF-κB and Akt pathways in cancer cells, we examined if suppression of Hsp90 is able to potentiate SMC3-induced cancer cell death. The results show that targeting Hsp90 does not interfere with SMC3-induced c-IAP1 degradation and TNF-α autocrine, the key processes for SMC3-induced cancer cell apoptosis. However, Hsp90 inhibitors effectively blocked SMC3-induced NF-κB activation through degradation of RIP1 and IKKβ, two key components of the NF-κB activation pathway, and reduced both the constitutive and SMC3-induced Akt activity through degradation of the Akt protein. Consistently, with the co-treatment of SMC3 and Hsp90 inhibitors, apoptosis was markedly sensitized and a synergistic cytotoxicity was observed. The results suggest that concurrent targeting c-IAP1 and Hsp90 by combination of SMC3 and Hsp90 inhibitors is an effective approach for improving the anticancer value of SMC3.Keywords
This publication has 38 references indexed in Scilit:
- The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapyExpert Opinion on Therapeutic Targets, 2009
- Association of Constitutive Nuclear Factor-JB Activation With Aggressive Aspects and Poor Prognosis in Cervical CancerInternational Journal of Gynecological Cancer, 2009
- Attenuating Smac mimetic compound 3‐induced NF‐κB activation by luteolin leads to synergistic cytotoxicity in cancer cellsJournal of Cellular Biochemistry, 2009
- Targeting the PI3K/AKT Pathway for the Treatment of Prostate CancerClinical Cancer Research, 2009
- IKKβ-mediated nuclear factor-κB activation attenuates smac mimetic–induced apoptosis in cancer cellsMolecular Cancer Therapeutics, 2009
- Akt-dependent and -independent mechanisms of mTOR regulation in cancerCellular Signalling, 2009
- Drug discovery approaches targeting the PI3K/Akt pathway in cancerOncogene, 2008
- Blockage of NF‐κB by IKKβ‐ or RelA‐siRNA rather than the NF‐κB super‐suppressor IκBα mutant potentiates adriamycin‐induced cytotoxicity in lung cancer cellsJournal of Cellular Biochemistry, 2008
- Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cellsMolecular Cancer Therapeutics, 2008
- TNF-α Induces Two Distinct Caspase-8 Activation PathwaysCell, 2008